Skip to main content
Erschienen in: Endocrine 2/2015

01.06.2015 | Original Article

Predictive value of serum apolipoprotein B/apolipoprotein A-I ratio in metabolic syndrome risk: a Chinese cohort study

verfasst von: Yu-Ching Chou, Jen-Chun Kuan, Chyi-Huey Bai, Tsan Yang, Wan-Yun Chou, Po-Chien Hsieh, San-Lin You, Lee-Ching Hwang, Chien-Hua Chen, Cheng-Yu Wei, Chien-An Sun

Erschienen in: Endocrine | Ausgabe 2/2015

Einloggen, um Zugang zu erhalten

Abstract

The purpose of this study was to evaluate whether the apolipoprotein B/apolipoprotein A-I (apoB/apoA-I) ratio is a promising risk predictor of metabolic syndrome (MetS) and to determine the optimal cut-off value of this ratio in detecting subjects with MetS in a Chinese population. A prospective study was conducted using a representative sample of non-institutionized people in Taiwan. A total of 3,343 participants with mean age (±SD) of 39.86 (±15.61) years old were followed up from 2002 to 2007. The primary outcome was the incidence of MetS. The MetS was defined according to a unified criterion established by several major organizations. There were 462 cases of incident MetS during a mean follow-up period of 5.26 years. A significantly stepwise increase in the incidence of MetS across quartiles of the apoB/apoA-I ratio was noted in both sexes after adjustment for potential confounders (p for trend <0.001). Compared with the lowest quartile of apoB/apoA-I ratio, participants in the highest quartile had a significantly higher risk of MetS in both men [adjusted hazard ratio (HR) = 6.29, 95 % confidence interval (CI) = 2.79–9.13] and women (adjusted HR = 3.82, 95 % CI = 1.06–6.63). Comparisons of receiver operating characteristics curves indicated that the predictive ability of apoB/apoA-I ratio to detect MetS was better than conventional lipid ratio measurements. Furthermore, the optimal cut-off value of apoB/apoA-I ratio for MetS diagnosis was 0.71 in men and 0.56 in women. These results suggest that an elevated apoB/apoA-I ratio might constitute a potentially crucial measure linked to the risk of developing MetS.
Literatur
1.
Zurück zum Zitat Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 285, 2486–2497 (2001) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 285, 2486–2497 (2001)
2.
Zurück zum Zitat J. Perk, G. De Backer, H. Gohlke, I. Graham, Z. Reiner, W.M. Verschuren, C. Albus, P. Benlian, G. Boysen, R. Cifkova, C. Deaton, S. Ebrahim, M. Fisher, G. Germano, R. Hobbs, A. Hoes, S. Karadeniz, A. Mezzani, E. Prescott, L. Ryden, M. Scherer, M. Swanne, W.J. Op Reimer, C. Vrints, D. Wood, J.L. Zamorano, F. Zannad, European Association for Cardiovascular Prevention & Rehabilitation (EACPR), European guidelines on cardiovascular disease prevention in clinical practice. The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Eur. Heart J. 33, 1635–1701 (2012)CrossRefPubMed J. Perk, G. De Backer, H. Gohlke, I. Graham, Z. Reiner, W.M. Verschuren, C. Albus, P. Benlian, G. Boysen, R. Cifkova, C. Deaton, S. Ebrahim, M. Fisher, G. Germano, R. Hobbs, A. Hoes, S. Karadeniz, A. Mezzani, E. Prescott, L. Ryden, M. Scherer, M. Swanne, W.J. Op Reimer, C. Vrints, D. Wood, J.L. Zamorano, F. Zannad, European Association for Cardiovascular Prevention & Rehabilitation (EACPR), European guidelines on cardiovascular disease prevention in clinical practice. The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Eur. Heart J. 33, 1635–1701 (2012)CrossRefPubMed
3.
Zurück zum Zitat S.M. Grundy, Low-density lipoprotein, non-high-density lipoprotein and apolipoprotein B as targets of lipid-lowering therapy. Circulation 106, 2526–2529 (2002)CrossRefPubMed S.M. Grundy, Low-density lipoprotein, non-high-density lipoprotein and apolipoprotein B as targets of lipid-lowering therapy. Circulation 106, 2526–2529 (2002)CrossRefPubMed
4.
Zurück zum Zitat J. Genest, J. Frohlich, G. Fodor, R. McPherson, Recommendations for the management of dyslipidemia and the prevention of cardiovascular disease: summary of the 2003 update. Can. Med. Assoc. J. 169, 921–924 (2003) J. Genest, J. Frohlich, G. Fodor, R. McPherson, Recommendations for the management of dyslipidemia and the prevention of cardiovascular disease: summary of the 2003 update. Can. Med. Assoc. J. 169, 921–924 (2003)
5.
Zurück zum Zitat O. Faergeman, Introduction: apolipoproteins and guidelines for prevention of cardiovascular disease. J. Intern. Med. 259, 434–436 (2006)CrossRefPubMed O. Faergeman, Introduction: apolipoproteins and guidelines for prevention of cardiovascular disease. J. Intern. Med. 259, 434–436 (2006)CrossRefPubMed
6.
Zurück zum Zitat S.O. Olofsson, O. Wiklund, J. Boren, Apolipoprotein A-I and B: biosynthesis, role in the development of atherosclerosis and targets for intervention against cardiovascular disease. Vasc. Health Risk Manag. 3, 491–502 (2007)PubMedCentralPubMed S.O. Olofsson, O. Wiklund, J. Boren, Apolipoprotein A-I and B: biosynthesis, role in the development of atherosclerosis and targets for intervention against cardiovascular disease. Vasc. Health Risk Manag. 3, 491–502 (2007)PubMedCentralPubMed
7.
Zurück zum Zitat A.D. Sniderman, C.D. Furberg, A. Keech, J.E.R. van Lennep, J. Frohlich, I. Jungner, G. Wallidus, Apolipoproteins versus lipids as indices of coronary risk and as targets for statin treatment. Lancet 361, 777–780 (2003)CrossRefPubMed A.D. Sniderman, C.D. Furberg, A. Keech, J.E.R. van Lennep, J. Frohlich, I. Jungner, G. Wallidus, Apolipoproteins versus lipids as indices of coronary risk and as targets for statin treatment. Lancet 361, 777–780 (2003)CrossRefPubMed
8.
Zurück zum Zitat A. Thompson, J. Danesh, Associations beteen apolipoprotein B, apolipoprotein AI, the apolipoprotein B/AI ratio, and coronary heart disease: a literature-based meta-analysis of prospective studies. J. Intern. Med. 259, 481–492 (2006)CrossRefPubMed A. Thompson, J. Danesh, Associations beteen apolipoprotein B, apolipoprotein AI, the apolipoprotein B/AI ratio, and coronary heart disease: a literature-based meta-analysis of prospective studies. J. Intern. Med. 259, 481–492 (2006)CrossRefPubMed
9.
Zurück zum Zitat G. Walldius, I. Jungner, Is there a better marker of cardiovascular risk than LDL cholesterol? Apolipoprotein B and A-I: new risk factors and targets for therapy. Nutr. Metab. Cardiovasc. Dis. 17, 565–571 (2007)CrossRefPubMed G. Walldius, I. Jungner, Is there a better marker of cardiovascular risk than LDL cholesterol? Apolipoprotein B and A-I: new risk factors and targets for therapy. Nutr. Metab. Cardiovasc. Dis. 17, 565–571 (2007)CrossRefPubMed
10.
Zurück zum Zitat M.J. McQueen, S. Hawken, X. Wang, S. Ounpuu, A. Sniderman, J. Probstfield, K. Steyn, J.E. Sanderson, M. Hasani, E. Volkova, K. Kazmi, S. Yusuf, INTERHEART study investigators. Lipids, lipoproteins, and apolipoproteins as risk markers of myocardial infarction in 52 countries (the INTERHEART study): a case-control study. Lancet 372, 224–233 (2008)CrossRefPubMed M.J. McQueen, S. Hawken, X. Wang, S. Ounpuu, A. Sniderman, J. Probstfield, K. Steyn, J.E. Sanderson, M. Hasani, E. Volkova, K. Kazmi, S. Yusuf, INTERHEART study investigators. Lipids, lipoproteins, and apolipoproteins as risk markers of myocardial infarction in 52 countries (the INTERHEART study): a case-control study. Lancet 372, 224–233 (2008)CrossRefPubMed
11.
Zurück zum Zitat J.H. Contois, J.P. McConnell, A.A. Sethi, G. Csako, S. Devaraj, D.M. Hoefner, G.R. Warnick, AACC Lipoproteins and Vascular Diseases Division Working Group on Best Practices. Apolipoprotein B and cardiovascular disease risk: position statement from the AACC Lipoproteins and Vascular Diseases Division Working Group on Best Practices. Clin. Chem. 55, 407–419 (2009)CrossRefPubMed J.H. Contois, J.P. McConnell, A.A. Sethi, G. Csako, S. Devaraj, D.M. Hoefner, G.R. Warnick, AACC Lipoproteins and Vascular Diseases Division Working Group on Best Practices. Apolipoprotein B and cardiovascular disease risk: position statement from the AACC Lipoproteins and Vascular Diseases Division Working Group on Best Practices. Clin. Chem. 55, 407–419 (2009)CrossRefPubMed
12.
Zurück zum Zitat E. Di Angelantonio, N. Sarwar, P. Perry, S. Kaptoge, K.K. Ray, A. Thompson, A.M. Wood, S. Lewington, N. Sattar, C.J. Packard, R. Collins, S.U. Thompson, J. Danesh, The Emerging Risk Factors Collaboration, Major lipids, apolipoproteins, and risk of vascular disease. JAMA 302, 1993–2000 (2009)CrossRefPubMed E. Di Angelantonio, N. Sarwar, P. Perry, S. Kaptoge, K.K. Ray, A. Thompson, A.M. Wood, S. Lewington, N. Sattar, C.J. Packard, R. Collins, S.U. Thompson, J. Danesh, The Emerging Risk Factors Collaboration, Major lipids, apolipoproteins, and risk of vascular disease. JAMA 302, 1993–2000 (2009)CrossRefPubMed
13.
Zurück zum Zitat J. Sierra-Johnson, R.M. Fisher, A. Romero-Corral, V.K. Somers, F. Lopez-Jimenez, J. Ohrvik, G. Wallidus, M.L. Hellenius, A. Hamsten, Concentration of apolipoprotein B is comparable with the apolipoprotein B/apolipoprotein A-I ratio and better than routine clinical lipid measurements in predicting coronary heart disease mortality: findings from a multi-ethnic US population. Eur. Heart J. 30, 710–717 (2009)CrossRefPubMedCentralPubMed J. Sierra-Johnson, R.M. Fisher, A. Romero-Corral, V.K. Somers, F. Lopez-Jimenez, J. Ohrvik, G. Wallidus, M.L. Hellenius, A. Hamsten, Concentration of apolipoprotein B is comparable with the apolipoprotein B/apolipoprotein A-I ratio and better than routine clinical lipid measurements in predicting coronary heart disease mortality: findings from a multi-ethnic US population. Eur. Heart J. 30, 710–717 (2009)CrossRefPubMedCentralPubMed
14.
Zurück zum Zitat G. Walldius, I. Jungner, A.H. Aastveit, I. Holme, C.D. Furberg, A.D. Sniderman, The apoB/apoA-I ratio is better than the cholesterol ratios to estimate the balance between plasma proatherogenic and antiatherogenic lipoproteins and to predict coronary risk. Clin. Chem. Lab. Med. 42, 1355–1363 (2004)CrossRefPubMed G. Walldius, I. Jungner, A.H. Aastveit, I. Holme, C.D. Furberg, A.D. Sniderman, The apoB/apoA-I ratio is better than the cholesterol ratios to estimate the balance between plasma proatherogenic and antiatherogenic lipoproteins and to predict coronary risk. Clin. Chem. Lab. Med. 42, 1355–1363 (2004)CrossRefPubMed
15.
Zurück zum Zitat G. Walldius, I. Jungner, The apoB/apoA-I ratio: a strong, new risk factor for cardiovascular disease and a target for lipid-lowering therapy: a review of the evidence. J. Intern. Med. 259, 493–519 (2006)CrossRefPubMed G. Walldius, I. Jungner, The apoB/apoA-I ratio: a strong, new risk factor for cardiovascular disease and a target for lipid-lowering therapy: a review of the evidence. J. Intern. Med. 259, 493–519 (2006)CrossRefPubMed
16.
Zurück zum Zitat G. Walldius, A.H. Aastveit, I. Jungner, Stroke mortality and the apoB/apoA-I ratio: results of the AMORIS prospective study. J. Intern. Med. 259, 259–266 (2006)CrossRefPubMed G. Walldius, A.H. Aastveit, I. Jungner, Stroke mortality and the apoB/apoA-I ratio: results of the AMORIS prospective study. J. Intern. Med. 259, 259–266 (2006)CrossRefPubMed
17.
Zurück zum Zitat J.J.P. Kastelein, W.A. Van der Steeg, I. Holme, M. Gaffney, N.B. Cater, P. Barter, P. Deedwania, A.G. Olsson, M. Boekholdt, D.A. Demicco, M. Szarek, J.C. LaRosa, T.R. Pedersen, S.M. Grundy, The TNT and IDEAL Study Groups, Lipids, apolipoproteins, and their ratios in relation to cardiovascular events with statin treatment. Circulation 117, 3002–3009 (2008)CrossRefPubMed J.J.P. Kastelein, W.A. Van der Steeg, I. Holme, M. Gaffney, N.B. Cater, P. Barter, P. Deedwania, A.G. Olsson, M. Boekholdt, D.A. Demicco, M. Szarek, J.C. LaRosa, T.R. Pedersen, S.M. Grundy, The TNT and IDEAL Study Groups, Lipids, apolipoproteins, and their ratios in relation to cardiovascular events with statin treatment. Circulation 117, 3002–3009 (2008)CrossRefPubMed
18.
Zurück zum Zitat G.P. Carnevale Schianca, R. Pedrazzoli, S. Onolfo, E. Colli, E. Cornetti, L. Bergamasco, G.P. Fra, E. Bartoli, ApoB/apoA-I ratio is better than LDL-C in detecting cardiovascular risk. Nut. Metab. Cardiovasc. Dis. 21, 406–411 (2011)CrossRef G.P. Carnevale Schianca, R. Pedrazzoli, S. Onolfo, E. Colli, E. Cornetti, L. Bergamasco, G.P. Fra, E. Bartoli, ApoB/apoA-I ratio is better than LDL-C in detecting cardiovascular risk. Nut. Metab. Cardiovasc. Dis. 21, 406–411 (2011)CrossRef
19.
Zurück zum Zitat J.H. Park, K.S. Hong, E.J. Lee, J. Lee, D.E. Kim, High levels of apolipoprotein B/AI ratio are associated with intracranial atherosclerotic stenosis. Stroke 42, 3040–3046 (2011)CrossRefPubMed J.H. Park, K.S. Hong, E.J. Lee, J. Lee, D.E. Kim, High levels of apolipoprotein B/AI ratio are associated with intracranial atherosclerotic stenosis. Stroke 42, 3040–3046 (2011)CrossRefPubMed
20.
21.
Zurück zum Zitat K.G.M.M. Alberti, R.H. Eckel, S.M. Grundy, P.Z. Zimmet, J.I. Cleeman, K.A. Donato, J.C. Fruchart, P.T. James, C.M. Loria, S.C. Smith Jr, Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 120, 1640–1645 (2009)CrossRefPubMed K.G.M.M. Alberti, R.H. Eckel, S.M. Grundy, P.Z. Zimmet, J.I. Cleeman, K.A. Donato, J.C. Fruchart, P.T. James, C.M. Loria, S.C. Smith Jr, Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 120, 1640–1645 (2009)CrossRefPubMed
22.
Zurück zum Zitat J. Sierra-Johnson, A. Romero-Corral, V.K. Somers, F. Lopez-Jimenez, G. Walldius, A. Hamsten, M.L. Hellenius, R.M. Fisher, ApoB/apoA-I ratio: an independent predictor of insulin resistance in US non-diabetic subjects. Eur. Heart J. 28, 2637–2643 (2007)CrossRefPubMed J. Sierra-Johnson, A. Romero-Corral, V.K. Somers, F. Lopez-Jimenez, G. Walldius, A. Hamsten, M.L. Hellenius, R.M. Fisher, ApoB/apoA-I ratio: an independent predictor of insulin resistance in US non-diabetic subjects. Eur. Heart J. 28, 2637–2643 (2007)CrossRefPubMed
23.
Zurück zum Zitat K. Wallenfeldt, L. Bokemark, J. Wikstrand, J. Hulthe, B. Fagerberg, Apolipoprotein B/apolipoprotein A-I in relation to the metabolic syndrome and change in carotid artery intima-media thickness during 3 years in middle-aged men. Stroke 35, 2248–2252 (2004)CrossRefPubMed K. Wallenfeldt, L. Bokemark, J. Wikstrand, J. Hulthe, B. Fagerberg, Apolipoprotein B/apolipoprotein A-I in relation to the metabolic syndrome and change in carotid artery intima-media thickness during 3 years in middle-aged men. Stroke 35, 2248–2252 (2004)CrossRefPubMed
24.
Zurück zum Zitat J. Sierra-Johnson, V.K. Somers, F.H.S. Kuniyoshi, C.A. Garza, W.L. Isley, A.S. Gami, F. Lopez-Jimenez, Comparison of apolipoprotein-B/apolipoprotein-AI in subjects with versus without the metabolic syndrome. Am. J. Cardiol. 98, 1369–1373 (2006)CrossRefPubMed J. Sierra-Johnson, V.K. Somers, F.H.S. Kuniyoshi, C.A. Garza, W.L. Isley, A.S. Gami, F. Lopez-Jimenez, Comparison of apolipoprotein-B/apolipoprotein-AI in subjects with versus without the metabolic syndrome. Am. J. Cardiol. 98, 1369–1373 (2006)CrossRefPubMed
25.
Zurück zum Zitat C. Pitsavos, D.B. Panagiotakos, J. Skoumas, L. Papadimitriou, C. Stefanadis, Risk stratification of apolipoprotein B, apolipoprotein AI, and apolipoprotein B/AI ratio on the prevalence of the metabolic syndrome: the ATTICA study. Angiology 59, 335–341 (2008)CrossRefPubMed C. Pitsavos, D.B. Panagiotakos, J. Skoumas, L. Papadimitriou, C. Stefanadis, Risk stratification of apolipoprotein B, apolipoprotein AI, and apolipoprotein B/AI ratio on the prevalence of the metabolic syndrome: the ATTICA study. Angiology 59, 335–341 (2008)CrossRefPubMed
26.
Zurück zum Zitat L. Zhong, Q. Li, Y. Jiang, Z. Liu, B. Wang, R. Luo, Q. Cheng, H. Qiang, The apoB/apoA1 ratio is associated with metabolic syndrome and its components in a Chinese population. Inflammation 33, 353–358 (2010)CrossRefPubMed L. Zhong, Q. Li, Y. Jiang, Z. Liu, B. Wang, R. Luo, Q. Cheng, H. Qiang, The apoB/apoA1 ratio is associated with metabolic syndrome and its components in a Chinese population. Inflammation 33, 353–358 (2010)CrossRefPubMed
27.
Zurück zum Zitat H. Belfki, S. Ben Ali, S. Bougatef, D. Ben Ahmed, N. Haddad, A. Jmal, M. Abdennebi, H. Ben Romdhane, The apolipoprotein B/apolipoprotein A1 ratio in relation to metabolic syndrome and its components in a sample of the Tunisian population. Exp. Mol. Pathol. 91, 622–625 (2011)CrossRefPubMed H. Belfki, S. Ben Ali, S. Bougatef, D. Ben Ahmed, N. Haddad, A. Jmal, M. Abdennebi, H. Ben Romdhane, The apolipoprotein B/apolipoprotein A1 ratio in relation to metabolic syndrome and its components in a sample of the Tunisian population. Exp. Mol. Pathol. 91, 622–625 (2011)CrossRefPubMed
28.
Zurück zum Zitat C.H. Jung, J.Y. Hwang, J.H. Yu, M.S. Shin, S.J. Bae, J.Y. Park, H.K. Kim, W.J. Lee, The value of apolipoprotein B/A1 ratio in the diagnosis of metabolic syndrome in a Korean population. Clin. Endocrinol. 77, 699–706 (2012)CrossRef C.H. Jung, J.Y. Hwang, J.H. Yu, M.S. Shin, S.J. Bae, J.Y. Park, H.K. Kim, W.J. Lee, The value of apolipoprotein B/A1 ratio in the diagnosis of metabolic syndrome in a Korean population. Clin. Endocrinol. 77, 699–706 (2012)CrossRef
29.
Zurück zum Zitat F. Jing, Y. Mao, J. Guo, Z. Zhang, Y. Li, Z. Ye, Y. Ding, J. Wang, M. Jin, K. Chen, The value of apolipoprotein B/apolipoprotein A1 ratio for metabolic syndrome diagnosis in a Chinese population: a cross-sectional study. Lipids Health Dis. 13, 81–87 (2014)CrossRefPubMedCentralPubMed F. Jing, Y. Mao, J. Guo, Z. Zhang, Y. Li, Z. Ye, Y. Ding, J. Wang, M. Jin, K. Chen, The value of apolipoprotein B/apolipoprotein A1 ratio for metabolic syndrome diagnosis in a Chinese population: a cross-sectional study. Lipids Health Dis. 13, 81–87 (2014)CrossRefPubMedCentralPubMed
30.
Zurück zum Zitat L.C. Hwang, C.H. Bai, C.J. Chen, K.L. Chien, Gender difference on the development of metabolic syndrome: a population-based study in Taiwan. Eur. J. Epidemiol. 22, 899–906 (2007)CrossRefPubMed L.C. Hwang, C.H. Bai, C.J. Chen, K.L. Chien, Gender difference on the development of metabolic syndrome: a population-based study in Taiwan. Eur. J. Epidemiol. 22, 899–906 (2007)CrossRefPubMed
31.
Zurück zum Zitat J.L. Kuk, C.I. Ardern, Age and sex differences in the clustering of metabolic syndrome factors: association with mortality risk. Diabetes Care 33, 2457–2461 (2010)CrossRefPubMedCentralPubMed J.L. Kuk, C.I. Ardern, Age and sex differences in the clustering of metabolic syndrome factors: association with mortality risk. Diabetes Care 33, 2457–2461 (2010)CrossRefPubMedCentralPubMed
32.
Zurück zum Zitat T. Yang, C.H. Chu, C.H. Bai, S.L. You, Y.C. Chou, W.Y. Chou, K.L. Chien, L.C. Hwang, T.C. Su, C.H. Tseng, C.A. Sun, Uric acid as a risk marker for metabolic syndrome: a Chinese cohort study. Atherosclerosis 220, 525–531 (2012)CrossRefPubMed T. Yang, C.H. Chu, C.H. Bai, S.L. You, Y.C. Chou, W.Y. Chou, K.L. Chien, L.C. Hwang, T.C. Su, C.H. Tseng, C.A. Sun, Uric acid as a risk marker for metabolic syndrome: a Chinese cohort study. Atherosclerosis 220, 525–531 (2012)CrossRefPubMed
33.
Zurück zum Zitat P. Benlian, C. Cansier, G. Hennache, O. Khallouf, P. Bayer, F. Duron, F. Carrat, R. Couderc, O. Chazouilleres, J. Bardet, P. Bouchard, R. Poupon, J. Masliah, G. Bereziat, Comparison of a new method for the direct and simultaneous assessment of LDL- and HDL-cholesterol with ultracentrifugation and established methods. Clin. Chem. 46, 493–505 (2000)PubMed P. Benlian, C. Cansier, G. Hennache, O. Khallouf, P. Bayer, F. Duron, F. Carrat, R. Couderc, O. Chazouilleres, J. Bardet, P. Bouchard, R. Poupon, J. Masliah, G. Bereziat, Comparison of a new method for the direct and simultaneous assessment of LDL- and HDL-cholesterol with ultracentrifugation and established methods. Clin. Chem. 46, 493–505 (2000)PubMed
34.
Zurück zum Zitat L.E. Chambless, R.P. McMahon, S.A. Brown, W. Patsch, G. Heiss, Y.L. Shen, Short-term intraindividual variability in lipoprotein measurements: the Atherosclerosis Risk in Communities (ARIC) Study. Am. J. Epidemiol. 136, 1069–1081 (1992)PubMed L.E. Chambless, R.P. McMahon, S.A. Brown, W. Patsch, G. Heiss, Y.L. Shen, Short-term intraindividual variability in lipoprotein measurements: the Atherosclerosis Risk in Communities (ARIC) Study. Am. J. Epidemiol. 136, 1069–1081 (1992)PubMed
35.
Zurück zum Zitat E.R. Delong, D.M. Delong, D.L. Clarke-Pearson, Comparing the area under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 44, 837–845 (1988)CrossRefPubMed E.R. Delong, D.M. Delong, D.L. Clarke-Pearson, Comparing the area under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 44, 837–845 (1988)CrossRefPubMed
36.
Zurück zum Zitat W.H. Pan, M.S. Lee, S.Y. Chuang, Y.C. Lin, M.L. Fu, Obesity pandemic, correlated factors and guidelines to define, screen and manage obesity in Taiwan. Obes. Rev. 9(Suppl. 1), 22–31 (2008)CrossRefPubMed W.H. Pan, M.S. Lee, S.Y. Chuang, Y.C. Lin, M.L. Fu, Obesity pandemic, correlated factors and guidelines to define, screen and manage obesity in Taiwan. Obes. Rev. 9(Suppl. 1), 22–31 (2008)CrossRefPubMed
37.
Zurück zum Zitat A.V. Chobanian, G.L. Bakris, H.R. Black, W.C. Cushman, L.A. Green, J.L. Izzo, D.W. Jones, B.J. Materson, S. Oparil, J.T. Wright, E.J. Roccella, the National High Blood Pressure Education Program Coordinating Committee. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 Report. JAMA 289, 2560–2572 (2003) A.V. Chobanian, G.L. Bakris, H.R. Black, W.C. Cushman, L.A. Green, J.L. Izzo, D.W. Jones, B.J. Materson, S. Oparil, J.T. Wright, E.J. Roccella, the National High Blood Pressure Education Program Coordinating Committee. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 Report. JAMA 289, 2560–2572 (2003)
38.
Zurück zum Zitat S. Elizabeth, C.M. Parrinello, D.B. Sacks, J. Coresh, Trends in prevalence and control of diabetes in the United States, 1988–1994 and 1999–2010. Ann. Intern. Med. 160, 517–525 (2014)CrossRef S. Elizabeth, C.M. Parrinello, D.B. Sacks, J. Coresh, Trends in prevalence and control of diabetes in the United States, 1988–1994 and 1999–2010. Ann. Intern. Med. 160, 517–525 (2014)CrossRef
39.
Zurück zum Zitat N.G. Forouhi, N. Sattar, CVD risk factors and ethnicity: a homogeneous relationship? Atheroscler. Suppl. 7, 11–19 (2006)CrossRefPubMed N.G. Forouhi, N. Sattar, CVD risk factors and ethnicity: a homogeneous relationship? Atheroscler. Suppl. 7, 11–19 (2006)CrossRefPubMed
40.
Zurück zum Zitat M.R. Taskinen, P.J. Barter, C. Ehnholm, D.R. Sullivan, K. Mann, J. Simes, J.D. Best, S. Hamwood, A.C. Keech, Ability of traditional lipid ratios and apolipoprotein ratios to predict cardiovascular risk in people with type 2 diabetes. Diabetologia 53, 1846–1855 (2010)CrossRefPubMed M.R. Taskinen, P.J. Barter, C. Ehnholm, D.R. Sullivan, K. Mann, J. Simes, J.D. Best, S. Hamwood, A.C. Keech, Ability of traditional lipid ratios and apolipoprotein ratios to predict cardiovascular risk in people with type 2 diabetes. Diabetologia 53, 1846–1855 (2010)CrossRefPubMed
41.
Zurück zum Zitat C.E. Ndumele, K. Matsushita, B. Astor, S.S. Virani, S. Mora, E.K. Williams, R.C. Hoogeveen, R.S. Blumenthal, A.R. Sharrett, C.M. Ballantyne, J. Coresh, Apolipoproteins do not add prognostic information beyond lipoprotein cholesterol measures among individuals with obesity and insulin resistance syndromes: the ARIC study. Eur. J. Prev. Cardiol. 21, 866–875 (2014)CrossRefPubMed C.E. Ndumele, K. Matsushita, B. Astor, S.S. Virani, S. Mora, E.K. Williams, R.C. Hoogeveen, R.S. Blumenthal, A.R. Sharrett, C.M. Ballantyne, J. Coresh, Apolipoproteins do not add prognostic information beyond lipoprotein cholesterol measures among individuals with obesity and insulin resistance syndromes: the ARIC study. Eur. J. Prev. Cardiol. 21, 866–875 (2014)CrossRefPubMed
42.
Zurück zum Zitat S.M. Grundy, Metabolic syndrome: a multiplex cardiovascular risk factor. J. Clin. Endocrinol. Metab. 92, 399–404 (2007)CrossRefPubMed S.M. Grundy, Metabolic syndrome: a multiplex cardiovascular risk factor. J. Clin. Endocrinol. Metab. 92, 399–404 (2007)CrossRefPubMed
43.
Zurück zum Zitat S. Kathiresan, J.D. Otvos, L.M. Sullivan, M.J. Keyes, E.J. Schaefer, P.W.F. Wilson, R.B. D’Agostino, R.S. Vasan, S.J. Robins, Increased small low-density lipoprotein particle number: a prominent feature of the metabolic syndrome in the Framingham Heart Study. Circulation 113, 20–29 (2006)CrossRefPubMed S. Kathiresan, J.D. Otvos, L.M. Sullivan, M.J. Keyes, E.J. Schaefer, P.W.F. Wilson, R.B. D’Agostino, R.S. Vasan, S.J. Robins, Increased small low-density lipoprotein particle number: a prominent feature of the metabolic syndrome in the Framingham Heart Study. Circulation 113, 20–29 (2006)CrossRefPubMed
44.
Zurück zum Zitat S. Marcovina, C.J. Packard, Measurement and meaning of apolipoprotein AI and apolipoprotein B plasma levels. J. Intern. Med. 259, 437–446 (2006)CrossRefPubMed S. Marcovina, C.J. Packard, Measurement and meaning of apolipoprotein AI and apolipoprotein B plasma levels. J. Intern. Med. 259, 437–446 (2006)CrossRefPubMed
45.
Zurück zum Zitat S.M. Marcovina, J.J. Albers, H. Kennedy, J.V. Mei, L.O. Henderson, W.H. Hannon, International Federation of Clinical Chemistry standardization project for measurements of apolipoproteins A-I and B. IV. Comparability of apolipoprotein B values by use of International Reference Material. Clin. Chem. 40, 586–592 (1994)PubMed S.M. Marcovina, J.J. Albers, H. Kennedy, J.V. Mei, L.O. Henderson, W.H. Hannon, International Federation of Clinical Chemistry standardization project for measurements of apolipoproteins A-I and B. IV. Comparability of apolipoprotein B values by use of International Reference Material. Clin. Chem. 40, 586–592 (1994)PubMed
46.
Zurück zum Zitat J. Liu, S.M. Grundy, W. Wang, S.C. Smith, G.L. Vega, Z. Wu, Z. Zeng, W. Wang, D. Zhao, Ethnic-specific criteria for the metabolic syndrome: evidence from China. Diabetes Care 29, 1414–1416 (2006)CrossRefPubMed J. Liu, S.M. Grundy, W. Wang, S.C. Smith, G.L. Vega, Z. Wu, Z. Zeng, W. Wang, D. Zhao, Ethnic-specific criteria for the metabolic syndrome: evidence from China. Diabetes Care 29, 1414–1416 (2006)CrossRefPubMed
47.
Zurück zum Zitat M.D. DeBoer, Ethnicity, obesity and the metabolic syndrome: implications on assessing risk and targeting intervention. Expert Rev. Endocrinol. Metab. 6, 279–289 (2011)CrossRefPubMedCentralPubMed M.D. DeBoer, Ethnicity, obesity and the metabolic syndrome: implications on assessing risk and targeting intervention. Expert Rev. Endocrinol. Metab. 6, 279–289 (2011)CrossRefPubMedCentralPubMed
Metadaten
Titel
Predictive value of serum apolipoprotein B/apolipoprotein A-I ratio in metabolic syndrome risk: a Chinese cohort study
verfasst von
Yu-Ching Chou
Jen-Chun Kuan
Chyi-Huey Bai
Tsan Yang
Wan-Yun Chou
Po-Chien Hsieh
San-Lin You
Lee-Ching Hwang
Chien-Hua Chen
Cheng-Yu Wei
Chien-An Sun
Publikationsdatum
01.06.2015
Verlag
Springer US
Erschienen in
Endocrine / Ausgabe 2/2015
Print ISSN: 1355-008X
Elektronische ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-014-0447-z

Weitere Artikel der Ausgabe 2/2015

Endocrine 2/2015 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Bei Herzinsuffizienz muss „Eisenmangel“ neu definiert werden!

16.05.2024 Herzinsuffizienz Nachrichten

Bei chronischer Herzinsuffizienz macht es einem internationalen Expertenteam zufolge wenig Sinn, die Diagnose „Eisenmangel“ am Serumferritin festzumachen. Das Team schlägt vor, sich lieber an die Transferrinsättigung zu halten.

Herzinfarkt mit 85 – trotzdem noch intensive Lipidsenkung?

16.05.2024 Hypercholesterinämie Nachrichten

Profitieren nach einem akuten Myokardinfarkt auch Betroffene über 80 Jahre noch von einer intensiven Lipidsenkung zur Sekundärprävention? Um diese Frage zu beantworten, wurden jetzt Registerdaten aus Frankreich ausgewertet.

ADHS-Medikation erhöht das kardiovaskuläre Risiko

16.05.2024 Herzinsuffizienz Nachrichten

Erwachsene, die Medikamente gegen das Aufmerksamkeitsdefizit-Hyperaktivitätssyndrom einnehmen, laufen offenbar erhöhte Gefahr, an Herzschwäche zu erkranken oder einen Schlaganfall zu erleiden. Es scheint eine Dosis-Wirkungs-Beziehung zu bestehen.

Erstmanifestation eines Diabetes-Typ-1 bei Kindern: Ein Notfall!

16.05.2024 DDG-Jahrestagung 2024 Kongressbericht

Manifestiert sich ein Typ-1-Diabetes bei Kindern, ist das ein Notfall – ebenso wie eine diabetische Ketoazidose. Die Grundsäulen der Therapie bestehen aus Rehydratation, Insulin und Kaliumgabe. Insulin ist das Medikament der Wahl zur Behandlung der Ketoazidose.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.